Company: WHWK
Filing Date: 2025-04-25
Form Type: 424B5
Source: 0001193125-25-097064
Chunk: 14

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-04-25
Form: 424B5
Chunk 14
---
 for general corporate purposes, which may include, among other things, working capital and funding research and development, and capital expenditures, including the
future preclinical and clinical development of the ADC Therapies.

The amounts and timing of our actual expenditures will depend on numerous
factors, including our development and commercialization efforts with respect to product candidates that we may develop in the future, as well as the amount of cash used in our operations. We therefore cannot estimate with certainty the amount of
net proceeds to be used for the purposes described above. We may find it necessary or advisable to use the net proceeds for other purposes, and we will have broad discretion in the application of the net proceeds. Pending the uses described above,
we plan to invest the net proceeds, if any, from this offering in short-term, investment-grade, interest-bearing securities.

S-12

PLAN OF DISTRIBUTION

We have previously entered into a sales agreement, dated March 17, 2022, as amended on April 25, 2025, with TD Cowen, under which we may issue
and sell from time to time up to $75,000,000 of our common stock through TD Cowen as our sales agent. Sales of our common stock, if any, will be made in negotiated transactions, including block trades or block sales, or at market prices by any
method that is deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act, including without limitation sales made through the Nasdaq Capital Market or any other trading market for our common stock, or
by any other method permitted by law. Sales pursuant to the sales agreement may be made through an affiliate of TD Cowen.

TD Cowen will offer our
common stock subject to the terms and conditions of the sales agreement on a daily basis or as otherwise agreed upon by us and TD Cowen. We will designate the maximum amount of common stock to be sold through TD Cowen on a daily basis or otherwise
determine such maximum amount together with TD Cowen. Subject to the terms and conditions of the sales agreement, TD Cowen will use its commercially reasonable efforts to sell on our behalf all of the shares of common stock requested to be sold by
us. We may instruct TD Cowen not to sell common stock if the sales cannot be effected at or above the price designated by us in any such instruction. TD Cowen or we may suspend the offering of our common stock being made through TD Cowen under